2025-04-13 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Analysis Report

**0) Summary of Key Figures:**

* **Cumulative Return (UNH):** 80.62%
* **Cumulative Return (VOO):** 66.36%
* **Return Difference:** 14.26%
* **Relative Divergence:** 58.4% (indicates UNH's performance is in the upper 58.4th percentile of its historical divergence from VOO)
* **Current Price:** $599.47
* **RSI:** 82.71 (Overbought)
* **PPO:** 1.58 (Potentially overbought)
* **Market Risk Indicator (MRI):** 0.47 (High Risk)

**1) Performance Comparison:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company providing a range of products and services.  Over the measured period, UNH significantly outperformed the S&P 500 (VOO), exhibiting a 14.26% higher cumulative return. While the relative divergence suggests UNH's outperformance is relatively high compared to its historical range, it's crucial to remember this is relative and doesn't guarantee future performance.

**Alpha and Beta Analysis:**

The provided data shows inconsistent Alpha and Beta values across different periods. While Alpha is consistently positive, indicating outperformance relative to the market, its magnitude fluctuates.  The Beta values are generally high, suggesting UNH's price is highly sensitive to market movements.  The significant negative CAGR in 2018-2020 highlights the risk associated with this stock.  Capitalization (Cap) consistently increased.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 64.0% | 56.1% | 35.0% | 0.1 | 181.0 |
| 2016-2018  | 55.0% | 63.9% | 37.0% | 0.2 | 207.3 |
| 2017-2019  | 41.0% | 63.9% | 11.0% | 0.3 | 248.8 |
| 2018-2020  | -20.0% | 63.9% | -45.0% | 0.5 | 301.7 |
| 2019-2021  | 34.0% | 60.8% | -20.0% | 0.6 | 438.0 |
| 2020-2022  | 28.0% | 67.1% | 22.0% | 0.6 | 468.4 |
| 2021-2023  | 35.0% | 67.6% | 18.0% | 0.4 | 472.1 |
| 2022-2024  | -27.0% | 68.8% | -44.0% | 0.3 | 460.8 |
| 2023-2025  | 3.0% | 73.2% | -11.0% | 0.2 | 548.3 |


**2) Recent Price Movement:**

* **Closing Price:** $599.47
* **5-Day Moving Average:** $570.03
* **20-Day Moving Average:** $529.99
* **60-Day Moving Average:** $513.98

The price is above all three moving averages, suggesting an upward trend. However, the relatively high RSI and PPO values raise concerns about potential overbought conditions.  The recent price increase of $0.85 (0.14%) suggests a modest upward movement, not a dramatic surge.

**3) Technical Indicators:**

* **RSI:** 82.71 – Significantly overbought, indicating potential for a price correction.
* **PPO:** 1.58 –  Also suggests overbought conditions.
* **Delta_Previous_Relative_Divergence:** 13.6 (+) -  Short-term upward trend, but unsustainable given the overbought indicators.
* **Expected Return:** 10.2% – This suggests a significant outperformance of the S&P 500 over the long term (2+ years), provided the current trends continue.  However, the risk indicators suggest caution.
* **Market Risk Indicator (MRI):** 0.47 – This falls in the High Risk category, highlighting the potential for significant price volatility.


**4) Recent Earnings Analysis:**

The earnings data shows some volatility. While revenue remains relatively stable, EPS shows fluctuations, including a significant negative value in one quarter.  Further investigation is needed to understand the reasons for this.  Note that the 2024-11-04 entry is duplicated.


| 날짜       | EPS   | 매출           |
|------------|-------|-----------------|
| 2024-11-04 | 6.56  | 100.82 B$       |
| 2024-08-09 | 4.58  | 98.86 B$       |
| 2024-05-09 | -1.53 | 99.80 B$       |
| 2023-11-06 | 6.31  | 92.36 B$       |
| 2024-11-04 | 6.31  | 92.36 B$       |


**5) Financial Information:**

Revenue remains relatively stable and high, with a healthy profit margin. However, Equity and ROE show volatility. The significant negative ROE in Q1 2024 needs further investigation to understand the underlying causes.


**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |
| 2024-03-31 | $99.80B   | 23.05%        |
| 2023-12-31 | $94.43B   | 23.30%        |

**Capital and Profitability:**

| Quarter | Equity     | ROE     |
|---------|------------|---------|
| 2024-12-31 | $92.66B   | 5.98%   |
| 2024-09-30 | $94.53B   | 6.41%   |
| 2024-06-30 | $89.36B   | 4.72%   |
| 2024-03-31 | $86.69B   | -1.63%  |
| 2023-12-31 | $88.76B   | 6.15%   |



**6) Overall Conclusion:**

UNH has shown strong historical outperformance compared to the S&P 500. However, current technical indicators (RSI, PPO, and MRI) suggest overbought conditions and a high-risk profile.  While the long-term expected return is positive, the volatility in earnings and ROE warrants caution.  Further investigation into the causes of the negative EPS and ROE in Q1 2024 is crucial before making any investment decisions.  The high Beta value suggests significant market sensitivity.  Investors should carefully consider their risk tolerance before investing in UNH.  A thorough fundamental analysis, including a deeper dive into the company's financials and future growth prospects, is recommended.
